Free Access
Med Sci (Paris)
Volume 25, Number 4, Avril 2009
Page(s) 423 - 430
Section Recherche et partenariat
Published online 15 April 2009
  1. Schmid F, Smith DA. Is declining innovation in the pharmaceutical industry a myth ? Drug Discov Today 2005; 10 : 1031–9. [Google Scholar]
  2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates ? Nat Rev Drug Discov 2004; 3 : 711–4. [Google Scholar]
  3. Kola I, Hazuda D. Innovation and greater probability of success in drug discovery and development: from target to biomarkers. Curr Opin Biotechnol 2005; 16 : 644–6. [Google Scholar]
  4. Sams-Dodd F. Strategies to optimize the validity of disease models in the drug discovery process. Drug Discov Today 2006; 11 : 355–63. [Google Scholar]
  5. Graeber TG, Sawyers CL. Cross-species comparisons of cancer signaling. Nat Genet 2005; 37 : 7–8. [Google Scholar]
  6. Kamb A. What’s wrong with our cancer models ? Nat Rev Drug Discov 2005; 4 : 161–5. [Google Scholar]
  7. Littman BH, Williams SA. The ultimate model organism: progress in experimental medicine. Nat Rev Drug Discov 2005; 4 : 631–8. [Google Scholar]
  8. Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006; 5 : 741–54. [Google Scholar]
  9. Chen H, Churfat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84 : 491–5. [Google Scholar]
  10. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405 : 857–65. [Google Scholar]
  11. Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet 2003; 19(11) : 660–6. [Google Scholar]
  12. Pasanen MK. SLC01B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16 : 873–9. [Google Scholar]
  13. Wang Y, et al. Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci USA 2009; 106 : 226–31. [Google Scholar]
  14. Caldwell MD. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111 : 4106–12. [Google Scholar]
  15. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2 : 566–80. [Google Scholar]
  16. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007; 6 : 287–93. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.